- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04324853
Helminth Infection During Pregnancy on Vitamin D Regulation: HELMVIT Study (HELMVIT)
Assessing the Effect of Maternal Helminth Infection on Vitamin D Regulation and on the Immune System of the Infant
Purpose: To examine whether helminth infection during pregnancy alters Vitamin-D-metabolism and reactivity of the child's immune system
Hypothesis: Helminth infection during pregnancy is associated with altered Vitamin D levels and Vitamin D receptor expression in the placenta and modified immune reactivity in the infant.
Study Overview
Status
Conditions
Detailed Description
Objectives The primary objective of the proposed research project is to study the impact of helminth infection in general and particularly of infection with S. haematobium during pregnancy on Vitamin D metabolism and its related factors as well as the impact of maternal infection on infants developing immune system and health.
Specific Objectives To assess the effect of maternal helminths infections on Vitamin D and vitamin-D-related factors in the serum of pregnant women and cord blood of their infants,
To assess the effect of helminth infection on placental biology:
Determine expression levels of VDR and inflammatory genes Investigate histologically the gestational age and other functional aspects of the placenta Determine the influence of helminth driven inflammation and helminth antigens on placental tissue by establishing a (co-)culture system using primary placental cells and a placental cell line To assess whether helminth infections influence the infant's peripheral immune system by analyzing composition, reactivity and lineage determination of fetal cord blood mononuclear cells (CBMCs) in relation to the maternal and fetal immune and Vitamin D status.
Current study focusing objectives In the present study the investigators explore if and how Vitamin D and its related signals are modulated by helminth infection and how helminth infection could thereby shape the developing immune system of the newborn by analyzing CBMCs.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Moyen Ogooué
-
Lambaréné, Moyen Ogooué, Gabon, BP 242
- Josiane Y Honkpehedji
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Pregnant women attending antenatal care from Lambaréné and Fougamou areas
- Pregnant women who have given written informed consent to the study for herself and for her unborn child and live infant.
Exclusion Criteria:
- Known of chronic infections and diseases(e.g. diabetes, HIV, Hepatitis B and C, anemia).
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Helminth negative
Pregnant women free of anyn helminths infection
|
Soil-transmitted helminth infections are among the most common infections worldwide and affect the poorest and most deprived communities.
They are transmitted by eggs present in human faeces which in turn contaminate soil in areas where sanitation is poor.
|
|
S. haematobium positive
Pregnant women infected with Schistosoma hematobium alone
|
Schistosomiasis is an acute and chronic parasitic disease caused by blood flukes (trematode worms) of the genus Schistosoma.Schistosomiasis is prevalent in tropical and subtropical areas, especially in poor communities without access to safe drinking water and adequate sanitation.
|
|
geohelminths positive
pregnant women infected with geohelminths alone
|
Soil-transmitted helminth infections are among the most common infections worldwide and affect the poorest and most deprived communities.
They are transmitted by eggs present in human faeces which in turn contaminate soil in areas where sanitation is poor.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Association between Schistosoma and helminth infection and Vitamin D levels.
Time Frame: 48 Months
|
Schistosoma hematobium in pregnancy is associated with vitamin D metabolism
|
48 Months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Association between Schistosoma infection and intrauterine growth restriction (IUGR) (defined as birth weight below the 10th birth weight percentile), stillbirth and premature delivery.
Time Frame: 48 Months
|
Schistosoma hematobium infection during pregnancy is associated with a birth weight born child
|
48 Months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Ayola A ADEGNIKA, MD, PhD, Centre de Recherche Médicale de Lambaréné
- Study Chair: Meral Esen, MD, University Hospital Tuebingen
- Study Director: Clarissa DaCosta, MD, Technical University of Munich
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PROT N°038/2018/SG/CNE
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vitamin D Deficiency
-
University Hospital, Clermont-FerrandTerminated
-
Rajavithi HospitalQueen Sirikit National Institute of Child HealthCompleted
-
Universidade de Passo FundoUnknownDeficiency, Vitamin DBrazil
-
Nutrition Institute, SloveniaEuropean Regional Development Fund; Vizera d.o.o.; Frutarom Etol d.o.o.CompletedVitamin B 12 Deficiency | Vitamin d Deficiency | Protein DeficiencySlovenia
-
Federal University of Rio Grande do SulCompletedDeficiency, Vitamin DBrazil
-
University of PaviaIstituti Clinici Scientifici Maugeri SpAUnknownVitamin D Deficiency | Vitamin D3 Deficiency | Vitamin DItaly
-
Wageningen UniversityDSM Nutritional Products, Inc.; Top Institute Food and NutritionCompletedElderly, Frail | Deficiency, Vitamin DNetherlands
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNot yet recruitingVitamin d DeficiencyChina
-
University of DelawareCompleted
-
University of Missouri, Kansas CityTruman Medical CenterWithdrawnVitamin d DeficiencyUnited States
Clinical Trials on Microscopy ( Urine filtration), UCAA test, qPCR,
-
Institut Pasteur de MadagascarJohns Hopkins Bloomberg School of Public Health; National Tuberculosis Program... and other collaboratorsCompleted
-
Stefanie KnoppErasmus Medical Center; Leiden University Medical Center; Natural History Museum... and other collaboratorsCompletedSchistosoma HaematobiumTanzania